Clinical scenario

This protocol covers patients with cutaneous sporotrichosis or lymphocutaneous sporotrichosis who have not achieved the expected response on first-line therapy.

Why escalation is needed

The standard initial approach for cutaneous and lymphocutaneous sporotrichosis is itraconazole taken daily, maintained for 2–4 weeks after all lesions have resolved — typically 3–6 months in total.

This next-line protocol applies when that course fails to produce clinical improvement of cutaneous lesions (normally expected within 4 weeks of starting therapy) or fails to achieve complete resolution of all lesions.

Next-line approach

When initial itraconazole is insufficient, the approach involves modifying or replacing the antifungal regimen — the full criteria, options, and sequencing are detailed in the complete protocol.

References

DOI: 10.1086/522765

For cutaneous and lymphocutaneous sporotrichosis, itraconazole (200 mg orally daily) is recommended to be given for 2–4 weeks after all lesions have resolved, usually a total of 3–6 months (A-II).

Patients who do not respond to treatment should be given a higher dosage of itraconazole (200 mg twice daily; A-II), terbinafine at a dosage of 500 mg orally twice daily (A-II), or SSKI initiated at a dosage of 5 drops (using a standard eye-dropper) 3 times daily, increasing as tolerated to 40–50 drops 3 times daily (A-II).

View source ↗

Treatment for cutaneous or lymphocutaneous sporotrichosis when itraconazole does not work

References